Mechanisms of physiological and pathological cardiac hypertrophy (original) (raw)

• Braunwald, E. Heart failure. JACC Heart Fail. 1, 1–20 (2013).
  Article PubMed Google Scholar
• Schiattarella, G. G. & Hill, J. A. Inhibition of hypertrophy is a good therapeutic strategy in ventricular pressure overload. Circulation 131, 1435–1447 (2015).
  Article PubMed Central PubMed Google Scholar
• Redfield, M. M. Heart failure with preserved ejection fraction. N. Engl. J. Med. 375, 1868–1877 (2016).
  Article PubMed Google Scholar
• Dunlay, S. M., Roger, V. L. & Redfield, M. M. Epidemiology of heart failure with preserved ejection fraction. Nat. Rev. Cardiol. 14, 591–602 (2017).
  Article PubMed Google Scholar
• Mohammed, S. F. et al. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation 131, 550–559 (2015).
  Article PubMed Google Scholar
• Maillet, M., van Berlo, J. H. & Molkentin, J. D. Molecular basis of physiological heart growth: fundamental concepts and new players. Nat. Rev. Mol. Cell Biol. 14, 38–48 (2013).
  Article PubMed Central CAS PubMed Google Scholar
• van Berlo, J. H., Maillet, M. & Molkentin, J. D. Signaling effectors underlying pathologic growth and remodeling of the heart. J. Clin. Invest. 123, 37–45 (2013).
  Article PubMed Central CAS PubMed Google Scholar
• Bernardo, B. C., Weeks, K. L., Pretorius, L. & McMullen, J. R. Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol. Ther. 128, 191–227 (2010).
  Article CAS PubMed Google Scholar
• Tham, Y. K., Bernardo, B. C., Ooi, J. Y., Weeks, K. L. & McMullen, J. R. Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch. Toxicol. 89, 1401–1438 (2015).
  Article CAS PubMed Google Scholar
• Shimizu, I. & Minamino, T. Physiological and pathological cardiac hypertrophy. J. Mol. Cell. Cardiol. 97, 245–262 (2016).
  Article CAS PubMed Google Scholar
• Perrino, C. et al. Intermittent pressure overload triggers hypertrophy-independent cardiac dysfunction and vascular rarefaction. J. Clin. Invest. 116, 1547–1560 (2006).
  Article PubMed Central CAS PubMed Google Scholar
• Vega, R. B., Konhilas, J. P., Kelly, D. P. & Leinwand, L. A. Molecular Mechanisms Underlying Cardiac Adaptation to Exercise. Cell Metab. 25, 1012–1026 (2017).
  Article PubMed Central CAS PubMed Google Scholar
• McMullen, J. R. et al. Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl Acad. Sci. USA 104, 612–617 (2007).
  Article PubMed Central CAS PubMed Google Scholar
• Tsujita, Y. et al. Nuclear targeting of Akt antagonizes aspects of cardiomyocyte hypertrophy. Proc. Natl Acad. Sci. USA 103, 11946–11951 (2006).
  Article PubMed Central CAS PubMed Google Scholar
• Turkbey, E. B. et al. The impact of obesity on the left ventricle: the Multi-Ethnic Study of Atherosclerosis (MESA). JACC Cardiovasc. Imaging 3, 266–274 (2010).
  Google Scholar
• Devereux, R. B. et al. Impact of diabetes on cardiac structure and function: the strong heart study. Circulation 101, 2271–2276 (2000).
  Article CAS PubMed Google Scholar
• Saltiel, A. R. & Kahn, C. R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799–806 (2001).
  Article CAS PubMed Google Scholar
• Neri Serneri, G. G. et al. Increased cardiac sympathetic activity and insulin-like growth factor-I formation are associated with physiological hypertrophy in athletes. Circ. Res. 89, 977–982 (2001).
  Article CAS PubMed Google Scholar
• Olszanecka, A., Dragan, A., Kawecka-Jaszcz, K., Fedak, D. & Czarnecka, D. Relationships of insulin-like growth factor-1, its binding proteins, and cardiometabolic risk in hypertensive perimenopausal women. Metabolism 69, 96–106 (2017).
  Article CAS PubMed Google Scholar
• Riehle, C. et al. Insulin receptor substrates are essential for the bioenergetic and hypertrophic response of the heart to exercise training. Mol. Cell. Biol. 34, 3450–3460 (2014).
  Article PubMed Central CAS PubMed Google Scholar
• Kim, J. et al. Insulin-like growth factor I receptor signaling is required for exercise-induced cardiac hypertrophy. Mol. Endocrinol. 22, 2531–2543 (2008).
  Article PubMed Central CAS PubMed Google Scholar
• McMullen, J. R. et al. The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J. Biol. Chem. 279, 4782–4793 (2004).
  Article CAS PubMed Google Scholar
• Troncoso, R., Ibarra, C., Vicencio, J. M., Jaimovich, E. & Lavandero, S. New insights into IGF-1 signaling in the heart. Trends Endocrinol. Metab. 25, 128–137 (2014).
  Article CAS PubMed Google Scholar
• McMullen, J. R. et al. Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl Acad. Sci. USA 100, 12355–12360 (2003).
  Article PubMed Central CAS PubMed Google Scholar
• Weeks, K. L. et al. Phosphoinositide 3-kinase p110alpha is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ. Heart Fail. 5, 523–534 (2012).
  Article CAS PubMed Google Scholar
• DeBosch, B. et al. Akt1 is required for physiological cardiac growth. Circulation 113, 2097–2104 (2006).
  Article CAS PubMed Google Scholar
• Skurk, C. et al. The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling. J. Biol. Chem. 280, 20814–20823 (2005).
  Article CAS PubMed Google Scholar
• O’Neill, B. T. et al. A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy. Cell Metab. 6, 294–306 (2007).
  Article PubMed Central CAS PubMed Google Scholar
• Bueno, O. F. et al. The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J. 19, 6341–6350 (2000).
  Article PubMed Central CAS PubMed Google Scholar
• Bostrom, P. et al. C/EBPbeta controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 143, 1072–1083 (2010).
  Article PubMed Central CAS PubMed Google Scholar
• Bezzerides, V. J. et al. CITED4 induces physiologic hypertrophy and promotes functional recovery after ischemic injury. JCI Insight 1, e85904 (2016).
  Article PubMed Central PubMed Google Scholar
• Pantos, C., Mourouzis, I. & Cokkinos, D. V. New insights into the role of thyroid hormone in cardiac remodeling: time to reconsider? Heart Fail. Rev. 16, 79–96 (2011).
  Article CAS PubMed Google Scholar
• Fisher, D. A. & Klein, A. H. Thyroid development and disorders of thyroid function in the newborn. N. Engl. J. Med. 304, 702–712 (1981).
  Article CAS PubMed Google Scholar
• Morkin, E. Control of cardiac myosin heavy chain gene expression. Microsc. Res. Tech. 50, 522–531 (2000).
  Article CAS PubMed Google Scholar
• Chang, K. C. et al. Thyroid hormone improves function and Ca2+ handling in pressure overload hypertrophy. Association with increased sarcoplasmic reticulum Ca2+-ATPase and alpha-myosin heavy chain in rat hearts. J. Clin. Invest. 100, 1742–1749 (1997).
  Article PubMed Central CAS PubMed Google Scholar
• Pantos, C. et al. Thyroid hormone at supra-physiological dose optimizes cardiac geometry and improves cardiac function in rats with old myocardial infarction. J. Physiol. Pharmacol. 60, 49–56 (2009).
  CAS PubMed Google Scholar
• Trivieri, M. G. et al. Cardiac-specific elevations in thyroid hormone enhance contractility and prevent pressure overload-induced cardiac dysfunction. Proc. Natl Acad. Sci. USA 103, 6043–6048 (2006).
  Article PubMed Central CAS PubMed Google Scholar
• Belke, D. D., Gloss, B., Swanson, E. A. & Dillmann, W. H. Adeno-associated virus-mediated expression of thyroid hormone receptor isoforms-alpha1 and -beta1 improves contractile function in pressure overload-induced cardiac hypertrophy. Endocrinology 148, 2870–2877 (2007).
  Article CAS PubMed Google Scholar
• Calvert, J. W. et al. Exercise protects against myocardial ischemia-reperfusion injury via stimulation of beta(3)-adrenergic receptors and increased nitric oxide signaling: role of nitrite and nitrosothiols. Circ. Res. 108, 1448–1458 (2011).
  Article PubMed Central CAS PubMed Google Scholar
• Huang, P. L. et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377, 239–242 (1995).
  Article CAS PubMed Google Scholar
• Lee, P. C. et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am. J. Physiol. 277, H1600–H1608 (1999).
  CAS PubMed Google Scholar
• Li, W. et al. Premature death and age-related cardiac dysfunction in male eNOS-knockout mice. J. Mol. Cell. Cardiol. 37, 671–680 (2004).
  Article CAS PubMed Google Scholar
• Rainer, P. P. & Kass, D. A. Old dog, new tricks: novel cardiac targets and stress regulation by protein kinase G. Cardiovasc. Res. 111, 154–162 (2016).
  Article PubMed Central CAS PubMed Google Scholar
• Tamirisa, P., Blumer, K. J. & Muslin, A. J. RGS4 inhibits G-protein signaling in cardiomyocytes. Circulation 99, 441–447 (1999).
  Article CAS PubMed Google Scholar
• Rogers, J. H. et al. RGS4 causes increased mortality and reduced cardiac hypertrophy in response to pressure overload. J. Clin. Invest. 104, 567–576 (1999).
  Article PubMed Central CAS PubMed Google Scholar
• Takimoto, E. et al. Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J. Clin. Invest. 119, 408–420 (2009).
  PubMed Central CAS PubMed Google Scholar
• de Waard, M. C. et al. Beneficial effects of exercise training after myocardial infarction require full eNOS expression. J. Mol. Cell. Cardiol. 48, 1041–1049 (2010).
  Article CAS PubMed Google Scholar
• Oka, T., Akazawa, H., Naito, A. T. & Komuro, I. Angiogenesis and cardiac hypertrophy: maintenance of cardiac function and causative roles in heart failure. Circ. Res. 114, 565–571 (2014).
  Article CAS PubMed Google Scholar
• Carmeliet, P. et al. Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat. Med. 5, 495–502 (1999).
  Article CAS PubMed Google Scholar
• Moslehi, J. J. Cardiovascular toxic effects of targeted cancer therapies. N. Engl. J. Med. 375, 1457–1467 (2016).
  Article CAS PubMed Google Scholar
• Hudlicka, O., Brown, M. & Egginton, S. Angiogenesis in skeletal and cardiac muscle. Physiol. Rev. 72, 369–417 (1992).
  Article CAS PubMed Google Scholar
• Hamasaki, S. et al. Attenuated coronary flow reserve and vascular remodeling in patients with hypertension and left ventricular hypertrophy. J. Am. Coll. Cardiol. 35, 1654–1660 (2000).
  Article CAS PubMed Google Scholar
• Togni, M. et al. Instantaneous coronary collateral function during supine bicycle exercise. Eur. Heart J. 31, 2148–2155 (2010).
  Article PubMed Google Scholar
• Mobius-Winkler, S. et al. Coronary collateral growth induced by physical exercise: results of the impact of intensive exercise training on coronary collateral circulation in patients with stable coronary artery disease (EXCITE) Trial. Circulation 133, 1438–1448 (2016).
  Article CAS PubMed Google Scholar
• Elkayam, U. Clinical characteristics of peripartum cardiomyopathy in the United States: diagnosis, prognosis, and management. J. Am. Coll. Cardiol. 58, 659–670 (2011).
  Article PubMed Google Scholar
• Patten, I. S. et al. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature 485, 333–338 (2012).
  Article PubMed Central CAS PubMed Google Scholar
• Goland, S. et al. Angiogenic imbalance and residual myocardial injury in recovered peripartum cardiomyopathy patients. Circ. Heart Fail. 9, e003349 (2016).
  Article CAS PubMed Google Scholar
• Damp, J. et al. Relaxin-2 and soluble Flt1 levels in peripartum cardiomyopathy: results of the multicenter IPAC study. JACC Heart Fail. 4, 380–388 (2016).
  Article PubMed Central PubMed Google Scholar
• Semenza, G. L. Hypoxia-inducible factor 1 and cardiovascular disease. Annu. Rev. Physiol. 76, 39–56 (2014).
  Article CAS PubMed Google Scholar
• Shiojima, I. et al. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J. Clin. Invest. 115, 2108–2118 (2005).
  Article PubMed Central CAS PubMed Google Scholar
• Shiojima, I. & Walsh, K. Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. Genes Dev. 20, 3347–3365 (2006).
  Article CAS PubMed Google Scholar
• Izumiya, Y. et al. Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 47, 887–893 (2006).
  Article CAS PubMed Google Scholar
• Sano, M. et al. p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload. Nature 446, 444–448 (2007).
  Article CAS PubMed Google Scholar
• Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14, 34–44 (2000).
  PubMed Central CAS PubMed Google Scholar
• Heineke, J. et al. Cardiomyocyte GATA4 functions as a stress-responsive regulator of angiogenesis in the murine heart. J. Clin. Invest. 117, 3198–3210 (2007).
  Article PubMed Central CAS PubMed Google Scholar
• Arany, Z. et al. HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1alpha. Nature 451, 1008–1012 (2008).
  Article CAS PubMed Google Scholar
• Torry, R. J. et al. Hypoxia increases placenta growth factor expression in human myocardium and cultured neonatal rat cardiomyocytes. J. Heart Lung Transplant 28, 183–190 (2009).
  Article PubMed Central PubMed Google Scholar
• Accornero, F. et al. Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism. Circ. Res. 109, 272–280 (2011).
  Article CAS PubMed Google Scholar
• Shindo, T. et al. Kruppel-like zinc-finger transcription factor KLF5/BTEB2 is a target for angiotensin II signaling and an essential regulator of cardiovascular remodeling. Nat. Med. 8, 856–863 (2002).
  Article CAS PubMed Google Scholar
• Chintalgattu, V. et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to load-induced stress. J. Clin. Invest. 120, 472–484 (2010).
  Article PubMed Central CAS PubMed Google Scholar
• Tromp, J. et al. Biomarker profiles in heart failure patients with preserved and reduced ejection fraction. J. Am. Heart Assoc. 6, e003989 (2017).
  Article PubMed Central PubMed Google Scholar
• Odiete, O., Hill, M. F. & Sawyer, D. B. Neuregulin in cardiovascular development and disease. Circ. Res. 111, 1376–1385 (2012).
  Article PubMed Central CAS PubMed Google Scholar
• Hirai, M. et al. Adaptor proteins NUMB and NUMBL promote cell cycle withdrawal by targeting ERBB2 for degradation. J. Clin. Invest. 127, 569–582 (2017).
  Article PubMed Central PubMed Google Scholar
• Waring, C. D. et al. The adult heart responds to increased workload with physiologic hypertrophy, cardiac stem cell activation, and new myocyte formation. Eur. Heart J. 35, 2722–2731 (2014).
  Article CAS PubMed Google Scholar
• Fukazawa, R. et al. Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via erbB4-dependent activation of PI3-kinase/Akt. J. Mol. Cell. Cardiol. 35, 1473–1479 (2003).
  Article CAS PubMed Google Scholar
• Bersell, K., Arab, S., Haring, B. & Kuhn, B. Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138, 257–270 (2009).
  Article CAS PubMed Google Scholar
• D’Uva, G. et al. ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation. Nat. Cell Biol. 17, 627–638 (2015).
  Article CAS PubMed Google Scholar
• Gemberling, M., Karra, R., Dickson, A. L. & Poss, K. D. Nrg1 is an injury-induced cardiomyocyte mitogen for the endogenous heart regeneration program in zebrafish. eLIFE 4, e05871 (2015).
  Article PubMed Central CAS Google Scholar
• Polizzotti, B. D. et al. Neuregulin stimulation of cardiomyocyte regeneration in mice and human myocardium reveals a therapeutic window. Sci. Transl. Med. 7, 281ra45 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• Lyon, R. C., Zanella, F., Omens, J. H. & Sheikh, F. Mechanotransduction in cardiac hypertrophy and failure. Circ. Res. 116, 1462–1476 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• De Acetis, M. et al. Cardiac overexpression of melusin protects from dilated cardiomyopathy due to long-standing pressure overload. Circ. Res. 96, 1087–1094 (2005).
  Article CAS PubMed Google Scholar
• Brancaccio, M. et al. Melusin, a muscle-specific integrin beta1-interacting protein, is required to prevent cardiac failure in response to chronic pressure overload. Nat. Med. 9, 68–75 (2003).
  Article CAS PubMed Google Scholar
• Fernandes, T., Barauna, V. G., Negrao, C. E., Phillips, M. I. & Oliveira, E. M. Aerobic exercise training promotes physiological cardiac remodeling involving a set of microRNAs. Am. J. Physiol. Heart Circ. Physiol. 309, H543–H552 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• Liu, X. et al. miR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell Metab. 21, 584–595 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• Chorghade, S. et al. Poly(A) tail length regulates PABPC1 expression to tune translation in the heart. eLIFE 6, e24139 (2017).
  Article PubMed Central PubMed Google Scholar
• Zhang, L. et al. Phospholipase cepsilon hydrolyzes perinuclear phosphatidylinositol 4-phosphate to regulate cardiac hypertrophy. Cell 153, 216–227 (2013).
  Article PubMed Central CAS PubMed Google Scholar
• Newton, A. C., Antal, C. E. & Steinberg, S. F. Protein kinase C mechanisms that contribute to cardiac remodelling. Clin. Sci. 130, 1499–1510 (2016).
  Article CAS Google Scholar
• Braz, J. C. et al. PKC-alpha regulates cardiac contractility and propensity toward heart failure. Nat. Med. 10, 248–254 (2004).
  Article CAS PubMed Google Scholar
• Kadambi, V. J. et al. Cardiac-specific overexpression of phospholamban alters calcium kinetics and resultant cardiomyocyte mechanics in transgenic mice. J. Clin. Invest. 97, 533–539 (1996).
  Article PubMed Central CAS PubMed Google Scholar
• Luo, W. et al. Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ. Res. 75, 401–409 (1994).
  Article CAS PubMed Google Scholar
• Ling, H. et al. Requirement for Ca2+/calmodulin-dependent kinase II in the transition from pressure overload-induced cardiac hypertrophy to heart failure in mice. J. Clin. Invest. 119, 1230–1240 (2009).
  Article PubMed Central PubMed Google Scholar
• Backs, J. et al. The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload. Proc. Natl Acad. Sci. USA 106, 2342–2347 (2009).
  Article PubMed Central PubMed Google Scholar
• Ago, T. et al. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell 133, 978–993 (2008).
  Article CAS PubMed Google Scholar
• Zhang, C. L. et al. Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy. Cell 110, 479–488 (2002).
  Article PubMed Central CAS PubMed Google Scholar
• Haberland, M., Montgomery, R. L. & Olson, E. N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet. 10, 32–42 (2009).
  Article PubMed Central CAS PubMed Google Scholar
• Gallo, P. et al. Inhibition of class I histone deacetylase with an apicidin derivative prevents cardiac hypertrophy and failure. Cardiovasc. Res. 80, 416–424 (2008).
  Article CAS PubMed Google Scholar
• Molkentin, J. D. et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93, 215–228 (1998).
  Article PubMed Central CAS PubMed Google Scholar
• Wilkins, B. J. et al. Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circ. Res. 94, 110–118 (2004).
  Article CAS PubMed Google Scholar
• Rose, B. A., Force, T. & Wang, Y. Mitogen-activated protein kinase signaling in the heart: angels versus demons in a heart-breaking tale. Physiol. Rev. 90, 1507–1546 (2010).
  Article CAS PubMed Google Scholar
• Lymperopoulos, A., Rengo, G. & Koch, W. J. Adrenergic nervous system in heart failure: pathophysiology and therapy. Circ. Res. 113, 739–753 (2013).
  Article CAS PubMed Google Scholar
• Sato, P. Y., Chuprun, J. K., Schwartz, M. & Koch, W. J. The evolving impact of g protein-coupled receptor kinases in cardiac health and disease. Physiol. Rev. 95, 377–404 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• Woodall, M. C., Ciccarelli, M., Woodall, B. P. & Koch, W. J. G protein-coupled receptor kinase 2: a link between myocardial contractile function and cardiac metabolism. Circ. Res. 114, 1661–1670 (2014).
  Article PubMed Central CAS PubMed Google Scholar
• Schumacher, S. M. & Koch, W. J. Noncanonical roles of G Protein-coupled receptor kinases in cardiovascular signaling. J. Cardiovasc. Pharmacol. 70, 129–141 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Martini, J. S. et al. Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes. Proc. Natl Acad. Sci. USA 105, 12457–12462 (2008).
  Article PubMed Central PubMed Google Scholar
• Hullmann, J. E. et al. GRK5-mediated exacerbation of pathological cardiac hypertrophy involves facilitation of nuclear NFAT activity. Circ. Res. 115, 976–985 (2014).
  Article PubMed Central CAS PubMed Google Scholar
• Traynham, C. J. et al. Differential role of G protein-coupled receptor kinase 5 in physiological versus pathological cardiac hypertrophy. Circ. Res. 117, 1001–1012 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• Gold, J. I., Gao, E., Shang, X., Premont, R. T. & Koch, W. J. Determining the absolute requirement of G protein-coupled receptor kinase 5 for pathological cardiac hypertrophy: short communication. Circ. Res. 111, 1048–1053 (2012).
  Article PubMed Central CAS PubMed Google Scholar
• Morel, E. et al. cAMP-binding protein Epac induces cardiomyocyte hypertrophy. Circ. Res. 97, 1296–1304 (2005).
  Article CAS PubMed Google Scholar
• Metrich, M. et al. Epac mediates beta-adrenergic receptor-induced cardiomyocyte hypertrophy. Circ. Res. 102, 959–965 (2008).
  Article CAS PubMed Google Scholar
• Pereira, L. et al. Epac2 mediates cardiac beta1-adrenergic-dependent sarcoplasmic reticulum Ca2+ leak and arrhythmia. Circulation 127, 913–922 (2013).
  Article PubMed Central CAS PubMed Google Scholar
• Okumura, S. et al. Epac1-dependent phospholamban phosphorylation mediates the cardiac response to stresses. J. Clin. Invest. 124, 2785–2801 (2014).
  Article PubMed Central CAS PubMed Google Scholar
• Pereira, L. et al. Novel Epac fluorescent ligand reveals distinct Epac1 versus Epac2 distribution and function in cardiomyocytes. Proc. Natl Acad. Sci. USA 112, 3991–3996 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• Saxton, R. A. & Sabatini, D. M. mTOR signaling in growth, metabolism, and disease. Cell 168, 960–976 (2017).
  Article PubMed Central CAS PubMed Google Scholar
• Sciarretta, S., Forte, M., Frati, G. & Sadoshima, J. New insights into the role of mTOR signaling in the cardiovascular system. Circ. Res. 122, 489–505 (2018).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, D. et al. MTORC1 regulates cardiac function and myocyte survival through 4E-BP1 inhibition in mice. J. Clin. Invest. 120, 2805–2816 (2010).
  Article PubMed Central CAS PubMed Google Scholar
• Sadoshima, J. & Izumo, S. Rapamycin selectively inhibits angiotensin II-induced increase in protein synthesis in cardiac myocytes in vitro. Potential role of 70-kD S6 kinase in angiotensin II-induced cardiac hypertrophy. Circ. Res. 77, 1040–1052 (1995).
  Article CAS PubMed Google Scholar
• Shioi, T. et al. Rapamycin attenuates load-induced cardiac hypertrophy in mice. Circulation 107, 1664–1670 (2003).
  Article CAS PubMed Google Scholar
• McMullen, J. R. et al. Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy. Mol. Cell. Biol. 24, 6231–6240 (2004).
  Article PubMed Central CAS PubMed Google Scholar
• Sciarretta, S. et al. mTORC2 regulates cardiac response to stress by inhibiting MST1. Cell Rep. 11, 125–136 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• Holtwick, R. et al. Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. J. Clin. Invest. 111, 1399–1407 (2003).
  Article PubMed Central CAS PubMed Google Scholar
• Takimoto, E. et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. 11, 214–222 (2005).
  Article CAS PubMed Google Scholar
• Lee, D. I. et al. Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature 519, 472–476 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• Pinto, A. R. et al. Revisiting cardiac cellular composition. Circ. Res. 118, 400–409 (2016).
  Article CAS PubMed Google Scholar
• Leask, A. Getting to the heart of the matter: new insights into cardiac fibrosis. Circ. Res. 116, 1269–1276 (2015).
  Article CAS PubMed Google Scholar
• Kakkar, R. & Lee, R. T. Intramyocardial fibroblast myocyte communication. Circ. Res. 106, 47–57 (2010).
  Article PubMed Central CAS PubMed Google Scholar
• Pellieux, C. et al. Dilated cardiomyopathy and impaired cardiac hypertrophic response to angiotensin II in mice lacking FGF-2. J. Clin. Invest. 108, 1843–1851 (2001).
  Article PubMed Central CAS PubMed Google Scholar
• Schultz, J. E. et al. Fibroblast growth factor-2 mediates pressure-induced hypertrophic response. J. Clin. Invest. 104, 709–719 (1999).
  Article PubMed Central CAS PubMed Google Scholar
• Kuwahara, F. et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 106, 130–135 (2002).
  Article CAS PubMed Google Scholar
• Divakaran, V. et al. Adaptive and maladptive effects of SMAD3 signaling in the adult heart after hemodynamic pressure overloading. Circ. Heart Fail. 2, 633–642 (2009).
  Article PubMed Central CAS PubMed Google Scholar
• Zhang, D. et al. TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. Nat. Med. 6, 556–563 (2000).
  Article CAS PubMed Google Scholar
• Koitabashi, N. et al. Pivotal role of cardiomyocyte TGF-beta signaling in the murine pathological response to sustained pressure overload. J. Clin. Invest. 121, 2301–2312 (2011).
  Article PubMed Central CAS PubMed Google Scholar
• Schafer, S. et al. IL-11 is a crucial determinant of cardiovascular fibrosis. Nature 552, 110–115 (2017).
  PubMed Central CAS PubMed Google Scholar
• Takeda, N. et al. Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. J. Clin. Invest. 120, 254–265 (2010).
  Article CAS PubMed Google Scholar
• Bang, C. et al. Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. J. Clin. Invest. 124, 2136–2146 (2014).
  Article PubMed Central CAS PubMed Google Scholar
• Frieler, R. A. & Mortensen, R. M. Immune cell and other noncardiomyocyte regulation of cardiac hypertrophy and remodeling. Circulation 131, 1019–1030 (2015).
  Article PubMed Central PubMed Google Scholar
• Testa, M. et al. Circulating levels of cytokines and their endogenous modulators in patients with mild to severe congestive heart failure due to coronary artery disease or hypertension. J. Am. Coll. Cardiol. 28, 964–971 (1996).
  Article CAS PubMed Google Scholar
• Melendez, G. C. et al. Interleukin 6 mediates myocardial fibrosis, concentric hypertrophy, and diastolic dysfunction in rats. Hypertension 56, 225–231 (2010).
  Article CAS PubMed Google Scholar
• Hirota, H., Yoshida, K., Kishimoto, T. & Taga, T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc. Natl Acad. Sci. USA 92, 4862–4866 (1995).
  Article PubMed Central CAS PubMed Google Scholar
• Zhao, L. et al. Deletion of interleukin-6 attenuates pressure overload-induced left ventricular hypertrophy and dysfunction. Circ. Res. 118, 1918–1929 (2016).
  Article PubMed Central CAS PubMed Google Scholar
• Hirota, H. et al. Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell 97, 189–198 (1999).
  Article CAS PubMed Google Scholar
• Kubota, T. et al. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-alpha. Circ. Res. 81, 627–635 (1997).
  Article CAS PubMed Google Scholar
• Sun, M. et al. Tumor necrosis factor-alpha mediates cardiac remodeling and ventricular dysfunction after pressure overload state. Circulation 115, 1398–1407 (2007).
  Article CAS PubMed Google Scholar
• Nishikawa, K. et al. Left ventricular hypertrophy in mice with a cardiac-specific overexpression of interleukin-1. Am. J. Physiol. Heart Circ. Physiol. 291, H176–H183 (2006).
  Article CAS PubMed Google Scholar
• Honsho, S. et al. Pressure-mediated hypertrophy and mechanical stretch induces IL-1 release and subsequent IGF-1 generation to maintain compensative hypertrophy by affecting Akt and JNK pathways. Circ. Res. 105, 1149–1158 (2009).
  Article CAS PubMed Google Scholar
• Van Tassell, B. W. et al. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am. J. Cardiol. 113, 321–327 (2014).
  Article CAS PubMed Google Scholar
• Van Tassell, B. W. et al. Interleukin-1 blockade in recently decompensated systolic heart failure: results from REDHART (Recently Decompensated Heart Failure Anakinra Response Trial). Circ. Heart Fail. 10, e004373 (2017).
  PubMed PubMed Central Google Scholar
• Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).
  Article CAS PubMed Google Scholar
• Verma, S. K. et al. Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-kappaB. Circulation 126, 418–429 (2012).
  Article PubMed Central CAS PubMed Google Scholar
• Sobirin, M. A. et al. Activation of natural killer T cells ameliorates postinfarct cardiac remodeling and failure in mice. Circ. Res. 111, 1037–1047 (2012).
  Article CAS PubMed Google Scholar
• Kallikourdis, M. et al. T cell costimulation blockade blunts pressure overload-induced heart failure. Nat. Commun. 8, 14680 (2017).
  Article PubMed Central PubMed Google Scholar
• Tirziu, D., Giordano, F. J. & Simons, M. Cell communications in the heart. Circulation 122, 928–937 (2010).
  Article PubMed Central PubMed Google Scholar
• Chen, W. Y., Hong, J., Gannon, J., Kakkar, R. & Lee, R. T. Myocardial pressure overload induces systemic inflammation through endothelial cell IL-33. Proc. Natl Acad. Sci. USA 112, 7249–7254 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• Sanada, S. et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538–1549 (2007).
  Article PubMed Central CAS PubMed Google Scholar
• Appari, M. et al. C1q-TNF-related protein-9 promotes cardiac hypertrophy and failure. Circ. Res. 120, 66–77 (2017).
  Article CAS PubMed Google Scholar
• Sun, Y. et al. C1q/tumor necrosis factor-related protein-9, a novel adipocyte-derived cytokine, attenuates adverse remodeling in the ischemic mouse heart via protein kinase A activation. Circulation 128, S113–S120 (2013).
  Article CAS PubMed Google Scholar
• Eder, P. & Molkentin, J. D. TRPC channels as effectors of cardiac hypertrophy. Circ. Res. 108, 265–272 (2011).
  Article CAS PubMed Google Scholar
• Kuwahara, K. et al. TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J. Clin. Invest. 116, 3114–3126 (2006).
  Article PubMed Central CAS PubMed Google Scholar
• Onohara, N. et al. TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J. 25, 5305–5316 (2006).
  Article PubMed Central CAS PubMed Google Scholar
• Bush, E. W. et al. Canonical transient receptor potential channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J. Biol. Chem. 281, 33487–33496 (2006).
  Article CAS PubMed Google Scholar
• Seo, K. et al. Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy. Proc. Natl Acad. Sci. USA 111, 1551–1556 (2014).
  Article PubMed Central CAS PubMed Google Scholar
• Takahashi, S. et al. Nitric oxide-cGMP-protein kinase G pathway negatively regulates vascular transient receptor potential channel TRPC6. J. Physiol. 586, 4209–4223 (2008).
  Article PubMed Central CAS PubMed Google Scholar
• Wu, X., Eder, P., Chang, B. & Molkentin, J. D. TRPC channels are necessary mediators of pathologic cardiac hypertrophy. Proc. Natl Acad. Sci. USA 107, 7000–7005 (2010).
  Article PubMed Central PubMed Google Scholar
• Makarewich, C. A. et al. Transient receptor potential channels contribute to pathological structural and functional remodeling after myocardial infarction. Circ. Res. 115, 567–580 (2014).
  Article PubMed Central CAS PubMed Google Scholar
• Correll, R. N. et al. STIM1 elevation in the heart results in aberrant Ca(2)(+) handling and cardiomyopathy. J. Mol. Cell. Cardiol. 87, 38–47 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• Troupes, C. D. et al. Role of STIM1 (stromal interaction molecule 1) in hypertrophy-related contractile dysfunction. Circ. Res. 121, 125–136 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Luo, X. et al. STIM1-dependent store-operated Ca(2)(+) entry is required for pathological cardiac hypertrophy. J. Mol. Cell. Cardiol. 52, 136–147 (2012).
  Article CAS PubMed Google Scholar
• Benard, L. et al. Cardiac Stim1 silencing impairs adaptive hypertrophy and promotes heart failure through inactivation of mTORC2/Akt signaling. Circulation 133, 1458–1471 (2016).
  Article PubMed Central CAS PubMed Google Scholar
• Burke, M. A., Cook, S. A., Seidman, J. G. & Seidman, C. E. Clinical and mechanistic insights into the genetics of cardiomyopathy. J. Am. Coll. Cardiol. 68, 2871–2886 (2016).
  Article PubMed Central PubMed Google Scholar
• Marian, A. J. & Braunwald, E. Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ. Res. 121, 749–770 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Davis, J. et al. A tension-based model distinguishes hypertrophic versus dilated cardiomyopathy. Cell 165, 1147–1159 (2016).
  Article PubMed Central CAS PubMed Google Scholar
• Teekakirikul, P. et al. Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta. J. Clin. Invest. 120, 3520–3529 (2010).
  Article PubMed Central CAS PubMed Google Scholar
• Papait, R. et al. Genome-wide analysis of histone marks identifying an epigenetic signature of promoters and enhancers underlying cardiac hypertrophy. Proc. Natl Acad. Sci. USA 110, 20164–20169 (2013).
  Article PubMed Central CAS PubMed Google Scholar
• Zhang, Q. J. et al. The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice. J. Clin. Invest. 121, 2447–2456 (2011).
  Article PubMed Central CAS PubMed Google Scholar
• Thienpont, B. et al. The H3K9 dimethyltransferases EHMT1/2 protect against pathological cardiac hypertrophy. J. Clin. Invest. 127, 335–348 (2017).
  Article PubMed Google Scholar
• Han, P. et al. Epigenetic response to environmental stress: assembly of BRG1-G9a/GLP-DNMT3 repressive chromatin complex on Myh6 promoter in pathologically stressed hearts. Biochim. Biophys. Acta 1863, 1772–1781 (2016).
  Article CAS PubMed PubMed Central Google Scholar
• Papait, R. et al. Histone methyltransferase G9a is required for cardiomyocyte homeostasis and hypertrophy. Circulation 136, 1233–1246 (2017).
  Article CAS PubMed Google Scholar
• Wang, Z. et al. The long noncoding RNA chaer defines an epigenetic checkpoint in cardiac hypertrophy. Nat. Med. 22, 1131–1139 (2016).
  Article PubMed Central CAS PubMed Google Scholar
• Fatica, A. & Bozzoni, I. Long non-coding RNAs: new players in cell differentiation and development. Nat. Rev. Genet. 15, 7–21 (2014).
  Article CAS PubMed Google Scholar
• Mercer, T. R., Dinger, M. E. & Mattick, J. S. Long non-coding RNAs: insights into functions. Nat. Rev. Genet. 10, 155–159 (2009).
  Article CAS PubMed Google Scholar
• Batista, P. J. & Chang, H. Y. Long noncoding RNAs: cellular address codes in development and disease. Cell 152, 1298–1307 (2013).
  Article PubMed Central CAS PubMed Google Scholar
• Harada, M. et al. MicroRNA regulation and cardiac calcium signaling: role in cardiac disease and therapeutic potential. Circ. Res. 114, 689–705 (2014).
  Article CAS PubMed Google Scholar
• Marks, A. R. Calcium cycling proteins and heart failure: mechanisms and therapeutics. J. Clin. Invest. 123, 46–52 (2013).
  Article PubMed Central CAS PubMed Google Scholar
• Meguro, T. et al. Cyclosporine attenuates pressure-overload hypertrophy in mice while enhancing susceptibility to decompensation and heart failure. Circ. Res. 84, 735–740 (1999).
  Article CAS PubMed Google Scholar
• Maillet, M. et al. Heart-specific deletion of CnB1 reveals multiple mechanisms whereby calcineurin regulates cardiac growth and function. J. Biol. Chem. 285, 6716–6724 (2010).
  Article CAS PubMed Google Scholar
• Maron, B. J., Doerer, J. J., Haas, T. S., Tierney, D. M. & Mueller, F. O. Sudden deaths in young competitive athletes: analysis of 1866 deaths in the United States, 1980–2006. Circulation 119, 1085–1092 (2009).
  Article PubMed Google Scholar
• Maron, B. J. Distinguishing hypertrophic cardiomyopathy from athlete’s heart physiological remodelling: clinical significance, diagnostic strategies and implications for preparticipation screening. Br. J. Sports Med. 43, 649–656 (2009).
  Article CAS PubMed Google Scholar
• Shimizu, I. et al. Excessive cardiac insulin signaling exacerbates systolic dysfunction induced by pressure overload in rodents. J. Clin. Invest. 120, 1506–1514 (2010).
  Article PubMed Central CAS PubMed Google Scholar
• Strom, C. C. et al. Expression profiling reveals differences in metabolic gene expression between exercise-induced cardiac effects and maladaptive cardiac hypertrophy. FEBS J. 272, 2684–2695 (2005).
  Article CAS PubMed Google Scholar
• Zhang, L. et al. Cardiac insulin-resistance and decreased mitochondrial energy production precede the development of systolic heart failure after pressure-overload hypertrophy. Circ. Heart Fail. 6, 1039–1048 (2013).
  Article CAS PubMed Google Scholar
• Liew, C. W. et al. Multiphasic regulation of systemic and peripheral organ metabolic responses to cardiac hypertrophy. Circ. Heart Fail. 10, e003864 (2017).
  Article PubMed Central CAS PubMed Google Scholar
• Doenst, T., Nguyen, T. D. & Abel, E. D. Cardiac metabolism in heart failure: implications beyond ATP production. Circ. Res. 113, 709–724 (2013).
  Article PubMed Central CAS PubMed Google Scholar
• Neubauer, S. The failing heart—an engine out of fuel. N. Engl. J. Med. 356, 1140–1151 (2007).
  Article PubMed Google Scholar
• Huss, J. M. et al. The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab. 6, 25–37 (2007).
  Article CAS PubMed Google Scholar
• Sung, M. M. et al. Cardiomyocyte-specific ablation of CD36 accelerates the progression from compensated cardiac hypertrophy to heart failure. Am. J. Physiol. Heart Circ. Physiol. 312, H552–H560 (2017).
  Article PubMed Google Scholar
• Boudina, S. et al. Contribution of impaired myocardial insulin signaling to mitochondrial dysfunction and oxidative stress in the heart. Circulation 119, 1272–1283 (2009).
  Article PubMed Central CAS PubMed Google Scholar
• Chiu, H. C. et al. A novel mouse model of lipotoxic cardiomyopathy. J. Clin. Invest. 107, 813–822 (2001).
  Article PubMed Central CAS PubMed Google Scholar
• Finck, B. N. et al. The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J. Clin. Invest. 109, 121–130 (2002).
  Article PubMed Central CAS PubMed Google Scholar
• Yagyu, H. et al. Lipoprotein lipase (LpL) on the surface of cardiomyocytes increases lipid uptake and produces a cardiomyopathy. J. Clin. Invest. 111, 419–426 (2003).
  Article PubMed Central PubMed Google Scholar
• Chiu, H. C. et al. Transgenic expression of fatty acid transport protein 1 in the heart causes lipotoxic cardiomyopathy. Circ. Res. 96, 225–233 (2005).
  Article CAS PubMed Google Scholar
• Son, N. H. et al. Cardiomyocyte expression of PPARgamma leads to cardiac dysfunction in mice. J. Clin. Invest. 117, 2791–2801 (2007).
  Article PubMed Central CAS PubMed Google Scholar
• Cheng, L. et al. Cardiomyocyte-restricted peroxisome proliferator-activated receptor-delta deletion perturbs myocardial fatty acid oxidation and leads to cardiomyopathy. Nat. Med. 10, 1245–1250 (2004).
  Article CAS PubMed Google Scholar
• Lai, L. et al. Energy metabolic reprogramming in the hypertrophied and early stage failing heart: a multisystems approach. Circ. Heart Fail. 7, 1022–1031 (2014).
  Article PubMed Central CAS PubMed Google Scholar
• Vega, R. B., Horton, J. L. & Kelly, D. P. Maintaining ancient organelles: mitochondrial biogenesis and maturation. Circ. Res. 116, 1820–1834 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• Aubert, G., Vega, R. B. & Kelly, D. P. Perturbations in the gene regulatory pathways controlling mitochondrial energy production in the failing heart. Biochim. Biophys. Acta 1833, 840–847 (2013).
  Article CAS PubMed Google Scholar
• Doenst, T. et al. Decreased rates of substrate oxidation ex vivo predict the onset of heart failure and contractile dysfunction in rats with pressure overload. Cardiovasc. Res. 86, 461–470 (2010).
  Article CAS PubMed Google Scholar
• Razeghi, P. et al. Metabolic gene expression in fetal and failing human heart. Circulation 104, 2923–2931 (2001).
  Article CAS PubMed Google Scholar
• Kolwicz, S. C. Jr et al. Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy. Circ. Res. 111, 728–738 (2012).
  Article PubMed Central CAS PubMed Google Scholar
• Choi, Y. S. et al. Preservation of myocardial fatty acid oxidation prevents diastolic dysfunction in mice subjected to angiotensin II infusion. J. Mol. Cell. Cardiol. 100, 64–71 (2016).
  Article PubMed Central CAS PubMed Google Scholar
• Burelle, Y. et al. Regular exercise is associated with a protective metabolic phenotype in the rat heart. Am. J. Physiol. Heart Circ. Physiol. 287, H1055–H1063 (2004).
  Article CAS PubMed Google Scholar
• Burkart, E. M. et al. Nuclear receptors PPARbeta/delta and PPARalpha direct distinct metabolic regulatory programs in the mouse heart. J. Clin. Invest. 117, 3930–3939 (2007).
  PubMed Central CAS PubMed Google Scholar
• Huss, J. M., Torra, I. P., Staels, B., Giguere, V. & Kelly, D. P. Estrogen-related receptor alpha directs peroxisome proliferator-activated receptor alpha signaling in the transcriptional control of energy metabolism in cardiac and skeletal muscle. Mol. Cell. Biol. 24, 9079–9091 (2004).
  Article PubMed Central CAS PubMed Google Scholar
• Fan, W. & Evans, R. PPARs and ERRs: molecular mediators of mitochondrial metabolism. Curr. Opin. Cell Biol. 33, 49–54 (2015).
  Article CAS PubMed Google Scholar
• Rowe, G. C., Jiang, A. & Arany, Z. PGC-1 coactivators in cardiac development and disease. Circ. Res. 107, 825–838 (2010).
  Article PubMed Central CAS PubMed Google Scholar
• Barger, P. M., Brandt, J. M., Leone, T. C., Weinheimer, C. J. & Kelly, D. P. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J. Clin. Invest. 105, 1723–1730 (2000).
  Article PubMed Central CAS PubMed Google Scholar
• Fan, W. & Evans, R. M. Exercise mimetics: impact on health and performance. Cell Metab. 25, 242–247 (2017).
  Article CAS PubMed Google Scholar
• Jager, S., Handschin, C., St-Pierre, J. & Spiegelman, B. M. AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc. Natl Acad. Sci. USA 104, 12017–12022 (2007).
  Article PubMed Central CAS PubMed Google Scholar
• Narkar, V. A. et al. AMPK and PPARdelta agonists are exercise mimetics. Cell 134, 405–415 (2008).
  Article PubMed Central CAS PubMed Google Scholar
• Vettor, R. et al. Exercise training boosts eNOS-dependent mitochondrial biogenesis in mouse heart: role in adaptation of glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 306, E519–E528 (2014).
  Article CAS PubMed Google Scholar
• Boudina, S. & Abel, E. D. Diabetic cardiomyopathy revisited. Circulation 115, 3213–3223 (2007).
  Article PubMed Google Scholar
• Schilling, J. D. & Mann, D. L. Diabetic cardiomyopathy: bench to bedside. Heart Fail. Clin. 8, 619–631 (2012).
  Article PubMed Central PubMed Google Scholar
• Szczepaniak, L. S., Victor, R. G., Orci, L. & Unger, R. H. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ. Res. 101, 759–767 (2007).
  Article CAS PubMed Google Scholar
• Rijzewijk, L. J. et al. Altered myocardial substrate metabolism and decreased diastolic function in nonischemic human diabetic cardiomyopathy: studies with cardiac positron emission tomography and magnetic resonance imaging. J. Am. Coll. Cardiol. 54, 1524–1532 (2009).
  Article CAS PubMed Google Scholar
• Rijzewijk, L. J. et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J. Am. Coll. Cardiol. 52, 1793–1799 (2008).
  Article PubMed Google Scholar
• Goldberg, I. J., Trent, C. M. & Schulze, P. C. Lipid metabolism and toxicity in the heart. Cell Metab. 15, 805–812 (2012).
  Article PubMed Central CAS PubMed Google Scholar
• Wang, G. et al. Direct binding to ceramide activates protein kinase Czeta before the formation of a pro-apoptotic complex with PAR-4 in differentiating stem cells. J. Biol. Chem. 280, 26415–26424 (2005).
  Article CAS PubMed Google Scholar
• Koves, T. R. et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab. 7, 45–56 (2008).
  Article CAS PubMed Google Scholar
• Bikman, B. T. & Summers, S. A. Ceramides as modulators of cellular and whole-body metabolism. J. Clin. Invest. 121, 4222–4230 (2011).
  Article PubMed Central CAS PubMed Google Scholar
• Chavez, J. A. & Summers, S. A. A ceramide-centric view of insulin resistance. Cell Metab. 15, 585–594 (2012).
  Article CAS PubMed Google Scholar
• Park, T. S. et al. Ceramide is a cardiotoxin in lipotoxic cardiomyopathy. J. Lipid Res. 49, 2101–2112 (2008).
  Article PubMed Central CAS PubMed Google Scholar
• Russo, S. B. et al. Ceramide synthase 5 mediates lipid-induced autophagy and hypertrophy in cardiomyocytes. J. Clin. Invest. 122, 3919–3930 (2012).
  Article PubMed Central CAS PubMed Google Scholar
• Son, N. H. et al. PPARgamma-induced cardiolipotoxicity in mice is ameliorated by PPARalpha deficiency despite increases in fatty acid oxidation. J. Clin. Invest. 120, 3443–3454 (2010).
  Article PubMed Central CAS PubMed Google Scholar
• Ji, R. et al. Increased de novo ceramide synthesis and accumulation in failing myocardium. JCI Insight 2, e82922 (2017).
  Article PubMed Central Google Scholar
• Reforgiato, M. R. et al. Inhibition of ceramide de novo synthesis as a postischemic strategy to reduce myocardial reperfusion injury. Basic Res. Cardiol. 111, 12 (2016).
  Article CAS PubMed Google Scholar
• Zhang, Y. et al. Endothelial Nogo-B regulates sphingolipid biosynthesis to promote pathological cardiac hypertrophy during chronic pressure overload. JCI Insight 1, e85484 (2016).
  Article PubMed Central PubMed Google Scholar
• Lee, S. Y. et al. Cardiomyocyte specific deficiency of serine palmitoyltransferase subunit 2 reduces ceramide but leads to cardiac dysfunction. J. Biol. Chem. 287, 18429–18439 (2012).
  Article PubMed Central CAS PubMed Google Scholar
• Schooneman, M. G., Vaz, F. M., Houten, S. M. & Soeters, M. R. Acylcarnitines: reflecting or inflicting insulin resistance? Diabetes 62, 1–8 (2013).
  Article CAS PubMed Google Scholar
• Bedi, K. C. Jr et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 133, 706–716 (2016).
  Article PubMed Central CAS PubMed Google Scholar
• Sansbury, B. E. et al. Metabolomic analysis of pressure-overloaded and infarcted mouse hearts. Circ. Heart Fail. 7, 634–642 (2014).
  Article PubMed Central CAS PubMed Google Scholar
• Ahmad, T. et al. Prognostic implications of long-chain acylcarnitines in heart failure and reversibility with mechanical circulatory support. J. Am. Coll. Cardiol. 67, 291–299 (2016).
  Article PubMed Central CAS PubMed Google Scholar
• Geraldes, P. & King, G. L. Activation of protein kinase C isoforms and its impact on diabetic complications. Circ. Res. 106, 1319–1331 (2010).
  Article PubMed Central CAS PubMed Google Scholar
• Jornayvaz, F. R. & Shulman, G. I. Diacylglycerol activation of protein kinase Cepsilon and hepatic insulin resistance. Cell Metab. 15, 574–584 (2012).
  Article PubMed Central CAS PubMed Google Scholar
• Chokshi, A. et al. Ventricular assist device implantation corrects myocardial lipotoxicity, reverses insulin resistance, and normalizes cardiac metabolism in patients with advanced heart failure. Circulation 125, 2844–2853 (2012).
  Article PubMed Central CAS PubMed Google Scholar
• Liu, L. et al. Cardiomyocyte-specific loss of diacylglycerol acyltransferase 1 (DGAT1) reproduces the abnormalities in lipids found in severe heart failure. J. Biol. Chem. 289, 29881–29891 (2014).
  Article PubMed Central CAS PubMed Google Scholar
• Newgard, C. B. Interplay between lipids and branched-chain amino acids in development of insulin resistance. Cell Metab. 15, 606–614 (2012).
  Article PubMed Central CAS PubMed Google Scholar
• Jang, C. et al. A branched-chain amino acid metabolite drives vascular fatty acid transport and causes insulin resistance. Nat. Med. 22, 421–426 (2016).
  Article PubMed Central CAS PubMed Google Scholar
• Sun, H. et al. Catabolic defect of branched-chain amino acids promotes heart failure. Circulation 133, 2038–2049 (2016).
  Article PubMed Central CAS PubMed Google Scholar
• Shao, D. & Tian, R. Glucose transporters in cardiac metabolism and hypertrophy. Compr. Physiol. 6, 331–351 (2015).
  Article PubMed Central PubMed Google Scholar
• Sen, S. et al. Glucose regulation of load-induced mTOR signaling and ER stress in mammalian heart. J. Am. Heart Assoc. 2, e004796 (2013).
  Article PubMed Central CAS PubMed Google Scholar
• Sharma, S., Guthrie, P. H., Chan, S. S., Haq, S. & Taegtmeyer, H. Glucose phosphorylation is required for insulin-dependent mTOR signalling in the heart. Cardiovasc. Res. 76, 71–80 (2007).
  Article CAS PubMed Google Scholar
• Ritterhoff, J. & Tian, R. Metabolism in cardiomyopathy: every substrate matters. Cardiovasc. Res. 113, 411–421 (2017).
  Article PubMed Central CAS PubMed Google Scholar
• Ussher, J. R., Jaswal, J. S. & Lopaschuk, G. D. Pyridine nucleotide regulation of cardiac intermediary metabolism. Circ. Res. 111, 628–641 (2012).
  Article CAS PubMed Google Scholar
• Mirtschink, P. et al. HIF-driven SF3B1 induces KHK-C to enforce fructolysis and heart disease. Nature 522, 444–449 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• Cotter, D. G., Schugar, R. C. & Crawford, P. A. Ketone body metabolism and cardiovascular disease. Am. J. Physiol. Heart Circ. Physiol. 304, H1060–H1076 (2013).
  Article PubMed Central CAS PubMed Google Scholar
• Lopaschuk, G. D. Metabolic modulators in heart disease: past, present, and future. Can. J. Cardiol. 33, 838–849 (2017).
  Article PubMed Google Scholar
• Lommi, J. et al. Blood ketone bodies in congestive heart failure. J. Am. Coll. Cardiol. 28, 665–672 (1996).
  Article CAS PubMed Google Scholar
• Aubert, G. et al. The failing heart relies on ketone bodies as a fuel. Circulation 133, 698–705 (2016).
  Article PubMed Central CAS PubMed Google Scholar
• Schugar, R. C. et al. Cardiomyocyte-specific deficiency of ketone body metabolism promotes accelerated pathological remodeling. Mol. Metab. 3, 754–769 (2014).
  Article PubMed Central CAS PubMed Google Scholar
• Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015).
  Article CAS PubMed Google Scholar
• Lopaschuk, G. D. & Verma, S. Empagliflozin’s fuel hypothesis: not so soon. Cell Metab. 24, 200–202 (2016).
  Article CAS PubMed Google Scholar
• Ferrannini, E. et al. Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes. Diabetes 65, 1190–1195 (2016).
  Article CAS PubMed Google Scholar
• Shimazu, T. et al. Suppression of oxidative stress by beta-hydroxybutyrate, an endogenous histone deacetylase inhibitor. Science 339, 211–214 (2013).
  Article CAS PubMed Google Scholar
• Taegtmeyer, H., Hems, R. & Krebs, H. A. Utilization of energy-providing substrates in the isolated working rat heart. Biochem. J. 186, 701–711 (1980).
  Article PubMed Central CAS PubMed Google Scholar
• Horton, J. L. et al. Mitochondrial protein hyperacetylation in the failing heart. JCI Insight 1, e84897 (2016).
  Article PubMed Central Google Scholar
• Nakamura, M. & Sadoshima, J. Heart over mind: metabolic control of white adipose tissue and liver. EMBO Mol. Med. 6, 1521–1524 (2014).
  Article PubMed Central CAS PubMed Google Scholar
• Shimano, M., Ouchi, N. & Walsh, K. Cardiokines: recent progress in elucidating the cardiac secretome. Circulation 126, e327–e332 (2012).
  Article PubMed Google Scholar
• de Bold, A. J. Thirty years of research on atrial natriuretic factor: historical background and emerging concepts. Can. J. Physiol. Pharmacol. 89, 527–531 (2011).
  Article CAS PubMed Google Scholar
• Grueter, C. E. et al. A cardiac microRNA governs systemic energy homeostasis by regulation of MED13. Cell 149, 671–683 (2012).
  Article PubMed Central CAS PubMed Google Scholar
• Baskin, K. K. et al. MED13-dependent signaling from the heart confers leanness by enhancing metabolism in adipose tissue and liver. EMBO Mol. Med. 6, 1610–1621 (2014).
  Article PubMed Central CAS PubMed Google Scholar
• Fuster, J. J., Ouchi, N., Gokce, N. & Walsh, K. Obesity-induced changes in adipose tissue microenvironment and their impact on cardiovascular disease. Circ. Res. 118, 1786–1807 (2016).
  Article PubMed Central CAS PubMed Google Scholar
• Ouchi, N., Parker, J. L., Lugus, J. J. & Walsh, K. Adipokines in inflammation and metabolic disease. Nat. Rev. Immunol. 11, 85–97 (2011).
  Article PubMed Central CAS PubMed Google Scholar
• Shibata, R. et al. Adiponectin-mediated modulation of hypertrophic signals in the heart. Nat. Med. 10, 1384–1389 (2004).
  Article PubMed Central CAS PubMed Google Scholar
• Fang, X. et al. Adipocyte-specific loss of PPARgamma attenuates cardiac hypertrophy. JCI Insight 1, e89908 (2016).
  Article PubMed Central PubMed Google Scholar
• Hardie, D. G., Ross, F. A. & Hawley, S. A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13, 251–262 (2012).
  Article PubMed Central CAS PubMed Google Scholar
• Mihaylova, M. M. & Shaw, R. J. The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat. Cell Biol. 13, 1016–1023 (2011).
  Article PubMed Central CAS PubMed Google Scholar
• Tian, R., Musi, N., D’Agostino, J., Hirshman, M. F. & Goodyear, L. J. Increased adenosine monophosphate-activated protein kinase activity in rat hearts with pressure-overload hypertrophy. Circulation 104, 1664–1669 (2001).
  Article CAS PubMed Google Scholar
• Shao, D. et al. A redox-dependent mechanism for regulation of AMPK activation by thioredoxin1 during energy starvation. Cell Metab. 19, 232–245 (2014).
• Kim, T. T. & Dyck, J. R. Is AMPK the savior of the failing heart? Trends Endocrinol. Metab. 26, 40–48 (2015).
  Article CAS PubMed Google Scholar
• Lee, C. F. et al. Normalization of NAD+ redox balance as a therapy for heart failure. Circulation 134, 883–894 (2016).
  Article PubMed Central CAS PubMed Google Scholar
• Nakamura, M., Bhatnagar, A. & Sadoshima, J. Overview of pyridine nucleotides review series. Circ. Res. 111, 604–610 (2012).
  Article PubMed Central CAS PubMed Google Scholar
• Koentges, C., Bode, C. & Bugger, H. SIRT3 in cardiac physiology and disease. Front. Cardiovasc. Med. 3, 38 (2016).
  Article PubMed Central CAS PubMed Google Scholar
• Sundaresan, N. R. et al. Sirt3 blocks the cardiac hypertrophic response by augmenting Foxo3a-dependent antioxidant defense mechanisms in mice. J. Clin. Invest. 119, 2758–2771 (2009).
  PubMed Central CAS PubMed Google Scholar
• Pillai, V. B. et al. Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. Nat. Commun. 6, 6656 (2015).
  Article CAS PubMed Google Scholar
• Zhang, R. et al. Short-term administration of nicotinamide mononucleotide preserves cardiac mitochondrial homeostasis and prevents heart failure. J. Mol. Cell. Cardiol. 112, 64–73 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Martin, A. S. et al. Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich’s ataxia cardiomyopathy model. JCI Insight 2, 93885 (2017).
  Article PubMed Google Scholar
• Sundaresan, N. R. et al. The sirtuin SIRT6 blocks IGF-Akt signaling and development of cardiac hypertrophy by targeting c-Jun. Nat. Med. 18, 1643–1650 (2012).
  Article PubMed Central CAS PubMed Google Scholar
• Tang, X. et al. SIRT2 acts as a cardioprotective deacetylase in pathological cardiac hypertrophy. Circulation 136, 2051–2067 (2017).
  Article CAS PubMed PubMed Central Google Scholar
• Alcendor, R. R. et al. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res. 100, 1512–1521 (2007).
  Article CAS PubMed Google Scholar
• Oka, S. et al. PPARalpha-Sirt1 complex mediates cardiac hypertrophy and failure through suppression of the ERR transcriptional pathway. Cell Metab. 14, 598–611 (2011).
  Article PubMed Central CAS PubMed Google Scholar
• Luo, Y. X. et al. SIRT4 accelerates Ang II-induced pathological cardiac hypertrophy by inhibiting manganese superoxide dismutase activity. Eur. Heart J. 38, 1389–1398 (2017).
  Article PubMed Google Scholar
• Tzahor, E. & Poss, K. D. Cardiac regeneration strategies: staying young at heart. Science 356, 1035–1039 (2017).
  Article PubMed Central CAS PubMed Google Scholar
• Eschenhagen, T. et al. Cardiomyocyte regeneration: a consensus statement. Circulation 136, 680–686 (2017).
  Article PubMed PubMed Central Google Scholar
• Cai, M. X. et al. Exercise training activates neuregulin 1/ErbB signaling and promotes cardiac repair in a rat myocardial infarction model. Life Sci. 149, 1–9 (2016).
  Article CAS PubMed Google Scholar
• Fero, M. L. et al. A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility inp27(Kip1)-deficient mice. Cell 85, 733–744 (1996).
  Article CAS PubMed Google Scholar
• Kiyokawa, H. et al. Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function ofp27(Kip1). Cell 85, 721–732 (1996).
  Article CAS PubMed Google Scholar
• Nakayama, K. et al. Mice lackingp27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85, 707–720 (1996).
  Article CAS PubMed Google Scholar
• Hauck, L. et al. Protein kinase CK2 links extracellular growth factor signaling with the control of p27(Kip1) stability in the heart. Nat. Med. 14, 315–324 (2008).
  Article CAS PubMed Google Scholar
• Matsuda, T. et al. Distinct roles of GSK-3alpha and GSK-3beta phosphorylation in the heart under pressure overload. Proc. Natl Acad. Sci. USA 105, 20900–20905 (2008).
  Article PubMed Central PubMed Google Scholar
• Pan, D. The hippo signaling pathway in development and cancer. Dev. Cell 19, 491–505 (2010).
  Article PubMed Central CAS PubMed Google Scholar
• Yu, F. X., Zhao, B. & Guan, K. L. Hippo pathway in organ size control, tissue homeostasis, and cancer. Cell 163, 811–828 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• Yamamoto, S. et al. Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J. Clin. Invest. 111, 1463–1474 (2003).
  Article PubMed Central CAS PubMed Google Scholar
• Heallen, T. et al. Hippo pathway inhibits Wnt signaling to restrain cardiomyocyte proliferation and heart size. Science 332, 458–461 (2011).
  Article PubMed Central CAS PubMed Google Scholar
• Maejima, Y. et al. Mst1 inhibits autophagy by promoting the interaction between Beclin1 and Bcl-2. Nat. Med. 19, 1478–1488 (2013).
  Article PubMed Central CAS PubMed Google Scholar
• Del, Re,D. P. et al. Mst1 promotes cardiac myocyte apoptosis through phosphorylation and inhibition of Bcl-xL. Mol. Cell 54, 639–650 (2014).
  Article CAS Google Scholar
• Nakamura, M., Zhai, P., Del Re, D. P., Maejima, Y. & Sadoshima, J. Mst1-mediated phosphorylation of Bcl-xL is required for myocardial reperfusion injury. JCI Insight 1, e86217 (2016).
  PubMed Central PubMed Google Scholar
• Huang, J., Wu, S., Barrera, J., Matthews, K. & Pan, D. The hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating yorkie, the drosophila homolog of YAP. Cell 122, 421–434 (2005).
  Article CAS PubMed Google Scholar
• von Gise, A. et al. YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. Proc. Natl Acad. Sci. USA 109, 2394–2399 (2012).
  Article Google Scholar
• Del Re, D. P. et al. Yes-associated protein isoform 1 (Yap1) promotes cardiomyocyte survival and growth to protect against myocardial ischemic injury. J. Biol. Chem. 288, 3977–3988 (2013).
  Article CAS PubMed Google Scholar
• Wang, P. et al. The alteration of Hippo/YAP signaling in the development of hypertrophic cardiomyopathy. Basic Res. Cardiol. 109, 435 (2014).
  Article CAS PubMed Google Scholar
• Xin, M. et al. Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size. Sci. Signal 4, ra70 (2011).
  Article PubMed Central CAS PubMed Google Scholar
• Xin, M. et al. Hippo pathway effector Yap promotes cardiac regeneration. Proc. Natl Acad. Sci. USA 110, 13839–13844 (2013).
  Article PubMed Central PubMed Google Scholar
• Lin, Z. et al. Cardiac-specific YAP activation improves cardiac function and survival in an experimental murine MI model. Circ. Res. 115, 354–363 (2014).
  Article PubMed Central CAS PubMed Google Scholar
• Li, J. et al. Alpha-catenins control cardiomyocyte proliferation by regulating Yap activity. Circ. Res. 116, 70–79 (2015).
  Article CAS PubMed Google Scholar
• Morikawa, Y., Heallen, T., Leach, J., Xiao, Y. & Martin, J. F. Dystrophin-glycoprotein complex sequesters Yap to inhibit cardiomyocyte proliferation. Nature 547, 227–231 (2017).
  Article PubMed Central CAS PubMed Google Scholar
• Leach, J. P. et al. Hippo pathway deficiency reverses systolic heart failure after infarction. Nature 550, 260–264 (2017).
  Article PubMed Central CAS PubMed Google Scholar
• Mo, J. S. et al. Cellular energy stress induces AMPK-mediated regulation of YAP and the Hippo pathway. Nat. Cell Biol. 17, 500–510 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• Wang, W. et al. AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat. Cell Biol. 17, 490–499 (2015).
  Article PubMed Central CAS PubMed Google Scholar
• DeRan, M. et al. Energy stress regulates hippo-YAP signaling involving AMPK-mediated regulation of angiomotin-like 1 protein. Cell Rep. 9, 495–503 (2014).
  Article PubMed Central CAS PubMed Google Scholar
• Smith, J. S., Lefkowitz, R. J. & Rajagopal, S. Biased signalling: from simple switches to allosteric microprocessors. Nat. Rev. Drug Discov. https://doi.org/10.1038/nrd.2017.229 (2018).